Stocks Trapped in Bearish Claws: AbbVie Inc. (NYSE:ABBV), RXi Pharmaceuticals Corporation (NASDAQ:RXII)

AbbVie Inc. (NYSE:ABBV) also run on active notice, stock price knocked up 0.32% after traded at $62.22 in most recent trading session.

AbbVie (ABBV) reported that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the company’s investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P), being evaluated for the treatment of chronic hepatitis C virus (HCV). In Phase 3 clinical studies, eight weeks of therapy with G/P achieved high sustained virologic response (SVR) rates across all major genotypes (GT 1-6) in patients without cirrhosis, which represents the majority of HCV patients. In patients with compensated cirrhosis, high SVR rates were achieved after 12 weeks of therapy.

“Our regimen of glecaprevir and pibrentasvir shows promise for patients by achieving high cure rates in Phase 3 clinical studies across all major hepatitis C genotypes,” said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie.

ABBV has price to earnings ratio of 16.74 and the price to current year EPS stands at 185.20%. Whereas the traders who further want to see about this, may be interested to see Price to next year’s EPS that would be 14.02%. The earning yield also gives right direction to lure investment, as the co has 4.11% dividend yield. Moving toward ratio analysis, it has current ratio of 1.80 and quick ratio was calculated as 1.60. The debt to equity ratio appeared as 5.77 for seeing its liquidity position.

Taking notice on volatility measures, price volatility of stock was 1.31% for a week and 2.20% for a month. The price volatility’s Average True Range for 14 days was 1.46. On these bases, analysts would recommend this stock as an “Active Revolving Stocks.” The firm attains analyst recommendation of 2.50 out of 1-5 scale with week’s performance of 1.10%. ABBV’s institutional ownership was registered as 68.30%, while insider ownership was 0.10%.

RXi Pharmaceuticals Corporation (NASDAQ:RXII) persists its position slightly strong in context of buying side, while shares price crashed down -38.67% during latest trading session.

Narrow down focus to other ratios, the co has current ratio of 2.50 that indicates if RXII lies in 1.3% to 3% then it is acceptable for both active and passive investors, but sometimes its varies industry to industry. Generally, it indicates good short-term financial strength. Street is more conscious on this after SunEdison, Inc. case. To make strengthen these views, the active industry firm has Quick Ratio of 2.50, which indicates firm has sufficient short-term assets to cover its immediate liabilities. In addition, the firm has debt to equity ratio of 0.00, sometimes its remain same with long term debt to equity ratio.

 

About Devon Leftovich

Leave a Reply

Your email address will not be published. Required fields are marked *